Elevation Oncology Gross Profit

Elevation Oncology (ELEV) currently reports a gross profit of $-9K as of March 2025. That compares with $19K in the prior-year period — down 147.4% year over year. That is below the Healthcare sector average of $67B. Use the charts on this page to explore Elevation Oncology's gross profit history and peer comparisons.

Elevation Oncology's gross profit decreased from $19K to $-9K — a 147.4% year-over-year decrease (period ending March 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Elevation Oncology's gross profit of $-9K is lower than the Healthcare sector average of $67B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Elevation Oncology reported $-9K in gross profit as of March 2025. That compares with $19K in the prior-year period — down 147.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current gross profit of $-9K, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $67B. From there, open related valuation or income-statement pages for Elevation Oncology, and consider following ELEV for alerts when major investors trade the stock.